EGFR and neoplasm: More recently, alternative mechanisms of resistance beyond genomics, mainly related to the tumor microenvironment, have been identified, specifically in patients treated with chemotherapy-based multi-drug treatment in first line of treatment (vs. anti-EGFR single treatment in heavily pretreated patients).